průvodce výběremPřihlásit
DOTAZY A FAKTA CBD PLUS

Použité zdroje

„Tato webová stránka obsahuje obecné informace o stravě, zdraví a výživě. Veškeré informace uvedené na této webové stránce, jakož i informace, které jsou prostřednictvím této webové stránky poskytovány, slouží pouze ke vzdělávacím účelům. Tyto informace nelze brát jako odborné rady, ani s nimi tak zacházet.

Sērum s.r.o. ve vztahu k informacím o zdraví, uvedeným na této webové stránce, neposkytuje žádné záruky. Nesmíte se spoléhat na informace, uvedené na této webové stránce, jako na alternativu rady od svého lékaře nebo jiného odborníka poskytujícího zdravotnickou péči.

Pokud si myslíte, že trpíte nebo byste mohl/a trpět jakoukoliv zdravotní obtíží, měl/a byste vyhledat okamžitou lékařskou pomoc. Nikdy neodkládejte vyhledání lékařské pomoci, neodmítejte lékařskou pomoc nebo nepřerušujte léčbu předepsanou vaším lékařem na základě informací, které jste nalezl/a na našich webových stránkách nebo které jsme vám poskytli. Žádná z informací zde uvedených není určena jako náhrada lékařské diagnózy a nelze takovou informaci považovat za lékařskou radu či doporučenou léčbu. V případě, že zvažujete provést jakoukoliv změnu ve svém životním stylu, stravě nebo výživě, obraťte se nejprve na svého lékaře nebo jiného odborníka poskytujícího zdravotnickou péči.

Tato webová stránka může obsahovat odkazy na webové stránky třetích stran. Tyto odkazy uvádíme pouze pro vaši informaci a žádným způsobem nepodporujeme žádnou z těchto webových stránek. Neneseme žádnou odpovědnost za obsah těchto webových stránek třetích stran, ani ve vztahu k informacím na těchto webových stránkách uvedených neposkytujeme žádné záruky. V případě, že se rozhodnete na tyto webové stránky třetích stran připojit či jakýmkoliv způsobem spoléhat na informace tam uvedené, činíte tak na vlastní riziko.

Tato webová stránka nepodporuje, neschvaluje ani neobhajuje dovolené či nedovolené užívání omamných či psychotropních látek. Veškeré informace uvedené na této webové stránce, jakož i informace, které jsou prostřednictvím této webové stránky poskytovány, slouží pouze ke vzdělávacím účelům. Sērum s.r.o. nemůže nést odpovědnost za obsah na jejich webových stránkách či na webových stránkách třetích stran, na které poskytujeme odkazy, pokud takový obsah podporuje, schvaluje či obhajuje užívání omamných či psychotropních látek či jiné nezákonné činnosti.
Sērum s.r.o. nemůže nést odpovědnost za jakékoliv nevhodné či nesprávné využití informací či služeb poskytovaných touto webovou stránkou a zříká se jakékoliv odpovědnosti za jakékoliv využití informací či služeb zde poskytovaných.“


Veškeré informace uvedené na webu www.serum.cz ve vztahu ke kanabinoidům byly čerpány ze zdrojů, které naleznete níže.


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161644/

  • Carlini EA. Research with marijuana in Brazil. Rev Bras Psiquiatr. (2010) 32(Suppl 1):S3–4. 10.1590/S1516-44462010000500002
  • Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr. (2008) 30:271–80. 10.1590/S1516-44462008000300015 
  • Mechoulam R, Zuardi AW, Kapczinski FP, Hallak JEC, Guimaraes FS, Crippa JAS, et al. Fluorinated CBD Compounds, Compositions and Uses Thereof. Pub. No.: WO/2014/ 108899. International Application No.: PCT/IL2014/050023. (2014)
  • Adams R, Hunt M, Clark JH. Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. J Am Chem Soc. (1940) 62:196–200. 10.1021/ja01858a058 
  • Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. (2009) 30:515–27. 10.1016/j.tips.2009.07.006 


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928495/

  • Aaltonen N., Kedzierska E., Orzelska-Górka J., Lehtonen M., Navia-Paldanius D., Jakupovic H., et al. (2016). In Vivo characterization of the ultrapotent monoacylglycerol lipase inhibitor {4-[bis-(benzo[d][1,3]dioxol-5-yl)methyl]-piperidin-1-yl}(1H-1,2,4-triazol-1-yl)methanone (JJKK-048). J. Pharmacol. Exp. Ther. 359 62–72. 10.1124/jpet.116.233114 
  • Aizpurua-Olaizola O., Elezgarai I., Rico-Barrio I., Zarandona I., Etxebarria N., Usobiaga A. (2017). Targeting the endocannabinoid system: future therapeutic strategies. Drug Discov. Today 22 105–110. 10.1016/j.drudis.2016.08.005 
  • Akerman S., Holland P. R., Goadsby P. J. (2007). Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. J. Pharmacol. Exp. Ther. 320 64–71. 10.1124/jpet.106.106971 
  • Akerman S., Kaube H., Goadsby P. J. (2003). Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J. Pharmacol. Exp. Ther. 309 56–63. 10.1124/jpet.103.059808
  • Baron E. P. (2015). Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it’s been. Headache 55 885–916. 10.1111/head.12570


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326553/

  • Baron EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: What a long strange trip it’s been … Headache. 2015 Jun;55(6):885–916. doi: 10.1111/head.12570.
  • Schluttenhofer C, Yuan L. Challenges towards revitalizing hemp: A multifaceted crop. Trends Plant Sci. 2017 Nov;22(11):917–29. doi: 10.1016/j.tplants.2017.08.004
  • Andre CM, Hausman JF, Guerriero G. Cannabis sativa: The plant of the thousand and one molecules. Front Plant Sci. 2016 Feb 4;7:19. doi: 10.3389/fpls.2016.00019.
  • Zlebnik NE, Cheer JF. Beyond the CB1 receptor: Is cannabidiol the answer for disorders of motivation? Annu Rev Neurosci. 2016 Jul 8;39:1–17. doi: 10.1146/annurev-neuro-070815-014038. 
  • Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014 Jun;55(6):791–802. doi: 10.1111/epi.12631.


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503660/

  • ABC News, USA Today, Stanford Medical Center Poll. Broad experience with pain sparks search for relief [online] 2005. URL: http://abcnews.go.com/images/Politics/979a1TheFightAgainstPain.pdf.
  • Abrams DI, Hilton JF, Leiser RJ, et al. Short-term effects of cannabinoids in patients with HIV-1 infection. A randomized, placbo-controlled clinical trial. Ann Intern Med. 2003;139:258–66.
  • Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68:515–21. 
  • Agarwal N, Pacher P, Tegeder I, et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci. 2007;10:870–9. 
  • Akerman S, Holland PR, Goadsby PJ. Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. J Pharmacol Exp Ther. 2007;320:64–71.


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338332/

  • Adams R, Hunt M, Clark J. Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. J Am Chem Soc. 1940;62:196–200.
  • Alhamoruni A, Lee A, Wright K, Larvin M, O'sullivan S. Pharmacological effects of cannabinoids on the Caco-2 cell culture model of intestinal permeability. J Pharmacol Exp Ther. 2010;335(1):92–102. 
  • Alhamoruni A, Wright K, Larvin M, O'sullivan S. Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability. Br J Pharmacol. 2012;165(8):2598–2610. 
  • Alvarez F, Lafuente H, Rey-Santano C, et al. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatr Res. 2008;64(6):653–658.
  • Appendino G, Gibbons S, Giana A, et al. Antibacterial cannabinoids from Cannabis sativa: a structure− activity study. J Nat Prod. 2008;71(8):1427–1430. 


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173676/

  • Mechoulam R, Hanus L. Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids. 2002;121:35–43
  • Mechoulam R, Shvo Y. Hashish. I. The structure of cannabidiol. Tetrahedron. 1963;19:2073–2078
  • Hanus LO, Tchilibon S, Ponde DE, et al. . Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors. Org Biomol Chem. 2005;3:1116–1123 
  • Gaoni Y, Mechoulam R. Isolation, structure, and partial suntheis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646–1647
  • Institute of Medicine; Joy JE, Watson SJ Jr., Benson JA. Marijuana and medicine: assessing the science base. National Academies Press: Washington, DC, 1999 


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834767/

  • American Psychiatry Association Diagnostic and Statistical Manual of Mental Disorders - DSM-5, 5th ed. AP Association Editor, Belo Horizonte; (2013).
  • Elsabbagh M, Divan G, Koh YJ, Kim YS, Kauchali S, Marcin C, et al. . Global prevalence of autism and other pervasive developmental disorders. Autism Res. (2012) 5:160–79. 10.1002/aur.239 
  • Committee on Children With Disabilities American academy of pediatrics: the pediatrician's role in the diagnosis and management of autistic spectrum disorder in children. Pediatrics. (2001) 107:1221–6. 10.1542/peds.107.5.1221
  • Mahajan R, Bernal MP, Panzer R, Whitaker A, Roberts W, Handen B, et al. . Clinical practice pathways for evaluation and medication choice for attention-deficit/hyperactivity disorder symptoms in autism spectrum disorders. Pediatrics. (2012) 130(Suppl 2S):125–38. 10.1542/peds.2012-0900J [PubMed] [CrossRef] [Google Scholar]
  • Kern JK, Geier DA, King PG, Sykes LK, Mehta JA, Geier MR. Shared brain connectivity issues, symptoms, and comorbidities in autism spectrum disorder, attention deficit/hyperactivity disorder, and tourette syndrome. Brain Connect. (2015) 5:321–35. 10.1089/brain.2014.0324 


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165951/

  • Aapro MS, Kirchner V, Terrey JP. The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: the effect of granisetron. Br J Cancer. 1994;69:957–960.
  • Aapro MS, Thuerlimann B, Sessa C, De Pree C, Bernhard J, Maibach R, Swiss Group for Clinical Cancer Research A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol. 2003;14:291–297. 
  • Abrahamov A, Abrahamov A, Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci. 1995;56:2097–2102.
  • Andrews PL, Bhandari P. Resiniferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret. Neuropharmacology. 1993;32:799–806.
  • Andrews PL, Horn CC. Signals for nausea and emesis: implications for models diseases. Auton Neurosci. 2006;125:100–115.


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470879/

  •  Figueredo VM. The time has come for physicians to take notice: the impact of psychosocial stressors on the heart. Am J Med. 2009;122(8):704–712. doi: 10.1016/j.amjmed.2009.05.001. 
  • Perk J, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Eur Heart J. 2012;33(13):1635–1701. doi: 10.1093/eurheartj/ehs092. 
  • Goldberg AD, et al. Ischemic, hemodynamic, and neurohormonal responses to mental and exercise stress. Experience from the Psychophysiological Investigations of Myocardial Ischemia Study (PIMI) Circulation. 1996;94(10):2402–2409. doi: 10.1161/01.CIR.94.10.2402.
  • Costa B. On the pharmacological properties of Delta9-tetrahydrocannabinol (THC) Chem Biodivers. 2007;4(8):1664–1677. doi: 10.1002/cbdv.200790146.
  • Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol. 2002;42(11 Suppl):11S–19S.


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736837/

  •  Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. Eur J Pharmacol. 1998;359(1):1–18. doi:10.1016/S0014-2999(98)00649-9
  • Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol. 2008;160:1–24. doi:10.1007/112_0505 
  • Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147(S1):S163–S171. 
  • Tóth KF, Ádám D, Bíró T, Oláh A. Cannabinoid signaling in the skin: therapeutic potential of the “C (ut) annabinoid” system. Molecules. 2019;24(5):918.
  • Tüting T, Gaffal E. Chapter 57 - regulatory role of cannabinoids for skin barrier functions and cutaneous inflammation In: Preedy VR, editor. Handbook of Cannabis and Related Pathologies. San Diego: Academic Press; 2017:543–549.


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023045/

  •  Battista N., Di Tommaso M., Bari M., Maccarrone M. The endocannabinoid system: An overview. Front. Behav. Neurosci. 2012;6:9. doi: 10.3389/fnbeh.2012.00009.
  • Morales P., Reggio P.H., Jagerovic N. An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol. Front. Pharmacol. 2017;8:422. doi: 10.3389/fphar.2017.00422. 
  • Rong C., Lee Y., Carmona N.E., Cha D.S., Ragguett R.M., Rosenblat J.D., Mansur R.B., Ho R.C., McIntyre R.S. Cannabidiol in medical marijuana: Research vistas and potential opportunities. Pharmacol. Res. 2017;121:213–218. doi: 10.1016/j.phrs.2017.05.005.
  • Iffland K., Grotenhermen F. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis Cannabinoid Res. 2017;2:139–154. doi: 10.1089/can.2016.0034. 
  • Lim K., See Y.M., Lee J. A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders. Clin. Psychopharmacol. Neurosci. 2017;15:301–312. doi: 10.9758/cpn.2017.15.4.301


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851925/

  • Akopian AN. Regulation of nociceptive transmission at the periphery via TRPA1-TRPV1 interactions. Curr Pharm Biotechnol. 2011;12:89–94.
  • Akopian AN, Ruparel NB, Patwardhan A, Hargreaves KM. Cannabinoids desensitize capsaicin and mustard oil responses in sensory neurons via TRPA1 activation. J Neurosci. 2008;8:1064–1075. 
  • Akopian AN, Ruparel NB, Jeske NA, Patwardhan A, Hargreaves KM. Role of ionotropic cannabinoid receptors in peripheral antipain and antihyperalgesia. Trends Pharmacol Sci. 2009;30:79–84. 
  • Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Mo FM, Liu J, Kunos G. Evidence for novel cannabinoid receptors. Pharmacol Ther. 2005;106:133–145. 
  • Berckmans RJ, Nieuwland R, Kraan MC, Schaap MC, Pots D, Smeets TJ, Sturk A, Tak PP. Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes. Arthritis Res Ther. 2005;7:R536–R544.


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400265/

  • O’Neill J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. Review on Antimicrobial Resistance; London, UK: 2016. pp. 1–81. 
  • Gilbert D.N., Guidos R.J., Boucher H.W., Talbot G.H., Spellberg B., Edwards J.E., Jr., Scheld W.M., Bradley J.S., John G., Bartlett J.G. The 10 x ’20 Initiative: Pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2010;50:1081–1083. doi: 10.1086/652237. 
  • Lodato E.M., Kaplan W. Background Paper 6.1 Antimicrobial Resistance. World Health Organization; Geneva, Switzerland: 2013.
  • O’Neill J. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. Review on Antimicrobial Resistance; London, UK: 2014. 
  • Cooper M.A., Shlaes D. Fix the antibiotics pipeline. Nature. 2011;472:32. doi: 10.1038/472032a.


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604171/

  • Kroenke K, Spitzer RL, Williams JB, Monahan PO, Lowe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146:317–325. doi: 10.7326/0003-4819-146-5-200703060-00004. 
  • Khan A, Leventhal RM, Khan S, Brown WA. Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database. J Affect Disord. 2002;68:183–190. doi: 10.1016/S0165-0327(01)00354-8. 
  • Olatunji BO, Cisler JM, Tolin DF. Quality of life in the anxiety disorders: a meta-analytic review. Clin Psychol Rev. 2007;27:572–581. doi: 10.1016/j.cpr.2007.01.015.
  • Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602. doi: 10.1001/archpsyc.62.6.593.
  • Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:629–640. doi: 10.1001/archpsyc.62.6.629. 


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514832/

  • ElSohly M.A., Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005;78:539–548. doi: 10.1016/j.lfs.2005.09.011. 
  • Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorganic Med. Chem. 2015;23:1377–1385. doi: 10.1016/j.bmc.2015.01.059. 
  • Bih C.I., Chen T., Nunn A.V., Bazelot M., Dallas M., Whalley B.J. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015;12:699–730. 
  • Sanchez A., Garcia-Merino A. Neuroprotective agents: cannabinoids. Clin. Immunol. 2012;142:57–67. doi: 10.1016/j.clim.2011.02.010.
  • Rajan T.S., Scionti D., Diomede F., Grassi G., Pollastro F., Piattelli A., Cocco L., Bramanti P., Mazzon E., Trubiani O. Gingival stromal cells as an in vitro model: Cannabidiol modulates genes linked with amyotrophic lateral sclerosis. J. Cell. Biochem. 2017;118:819–828. doi: 10.1002/jcb.25757. 

Nenašli jste odpověď?

napsat dotaz